RT Journal Article
SR Electronic
T1 The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial
JF BMJ Open Diabetes Research & Care
JO BMJ Open Diab Res Care
FD American Diabetes Association
SP e000079
DO 10.1136/bmjdrc-2014-000079
VO 3
IS 1
A1 Andreea Soare
A1 Rossella Del Toro
A1 Elena Roncella
A1 Yeganeh Manon Khazrai
A1 Silvia Angeletti
A1 Laura Dugo
A1 Sara Fallucca
A1 Lucia Fontana
A1 Maria Altomare
A1 Valeria Formisano
A1 Francesca Capata
A1 Rosaria Gesuita
A1 Silvia Manfrini
A1 Francesco Fallucca
A1 Mario Pianesi
A1 Paolo Pozzilli
A1 for the MADIAB Group
YR 2015
UL http://drc.bmj.com/content/3/1/e000079.abstract
AB Introduction Current guidelines for the management of type 2 diabetes (T2D) emphasize diet as essential therapy. However, the effect of diet on systemic inflammation remains unclear. We investigated the effects of consuming a macrobiotic Ma-Pi 2 diet versus a standard recommended diet (control diet) on markers of inflammation in patients with T2D.Methods This was a post hoc analysis of the MADIAB trial, a 21-day randomized controlled trial conducted in 51 patients (25 males and 26 females) with T2D. Patients were randomized 1:1 to the Ma-Pi 2 macrobiotic diet or a control diet based on dietary guidelines for T2D. Biological antioxidant potential of plasma and circulating levels of high-sensitivity C reactive protein, interleukin-6, tumor necrosis factor-α, and insulin-like growth factor-1 were assessed.Results After 21 days on the Ma-Pi 2 or control diet, markers of inflammation were reduced in both groups. The antioxidant potential of plasma improved significantly in the Ma-Pi group. A significant reduction in insulin growth factor-1 was observed in the Ma-Pi group versus control group (p<0.001).Conclusions Findings of this post hoc analysis demonstrated that the Ma-Pi 2 diet is a safe dietary strategy to reduce levels of the markers of insulin resistance and inflammation, compared with baseline values, in the short term. Furthermore, the Ma-Pi 2 diet was superior to the control diet in reducing insulin growth factor-1 and may be beneficial for patients with T2D.Trial registration number Current Controlled Trials ISRCTN10467793.